Close
Nordic 9Nordic 9

Oncode Oncology Bridge Fund (investor - Venture Capital)

Netherlands oncodeinstitute.nl
See something wrong or missing? Let us know
Offices:Utrecht
Average round investment:17.52M USD
Average number per year:1.0
Distribution: 2025 (1)2024 (1)
Portfolio companies: Netherlands Laigo BioNetherlands Flindr Therapeutics
Mostly invests in: Netherlands Netherlands (2) Pharma (2)

2 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Oncode Oncology Bridge Fund

Name Criteria
United States Chris Gibson
83%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Netherlands Curie Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States DaVita Venture Group
83%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Netherlands Swanbridge Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Initialized Capital
83%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Belgium Fundplus
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.6
  • Active last 12 months: Yes
China China Grand Pharmaceutical and Healthcare Holdings
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Sweden Flerie Invest
82%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Norway Hadean Ventures
81%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 3.2
  • Active last 12 months: Yes
Netherlands LIOF
80%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Top